Company: RGNT
Filing Date: 2025-09-09
Form Type: 8-A12B
Source: 0001213900-25-086109
Chunk: 1

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-09
Form: 8-A12B
Chunk 1
---
), originally filed with the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended (the “Securities Act”) on March 11, 2025, as subsequently
amended (the “Registration Statement”), and any prospectus that constitutes part of the Registration Statement
and that is subsequently filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, which information
shall be deemed to be incorporated herein by reference.

Item 2. Exhibits.

Pursuant to the Instructions as to Exhibits for
Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on NYSE American, LLC, and the
securities registered hereby are not being registered pursuant to Section 12(g) of the , as
amended.

<div align='center'>1

SIGNATURE</div>

Pursuant to the requirements of Section 12 of
the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized.

| Regentis Biomaterials Ltd. |                         |
| By:                        | /s/ Dr. Eli Hazum       |
| Name:                      | Dr. Eli Hazum           |
| Title:                     | Chief Executive Officer |

Dated: September 9, 2025

<div align='center'>2</div>